MedTrace Logo

Protein and Performance (PROPER) in Endurance Athletes

NCT05426447 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-05-07

No results posted yet for this study

Summary

The present study is a parallel group design with randomised allocation to either a 1) reduced protein diet (RP) or a 2) normal protein diet (NP). The two groups will be pair-matched based on habitual dietary protein intake, endurance training, endurance performance, and sex.

The aim of the study is to investigate the effects of reducing dietary protein (\~1g protein/kg body mass) compared to an eucaloric normal protein diet (\~2g protein/kg body mass) for 6 weeks in well-trained endurance athletes on endurance performance, body composition, skeletal muscle protein synthesis, and health-related outcomes.

The hypothesis is that endurance performance will maintain or even be improved in well-trained endurance athletes after a 6-week dietary intervention of an eucaloric, protein reduced diet compared to a normal protein rich diet.

Conditions

  • Diet, Healthy
  • Protein Deficiency

Interventions

OTHER

Dietary intervention of reduced protein intake

6-wk dietary intervention of reduced protein intake

OTHER

Dietary intervention of normal protein intake

6-wk dietary intervention of normal protein intake

Sponsors & Collaborators

  • Maastricht University Medical Center

    collaborator OTHER

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Nicki W Almquist, Post Doc · University of Copenhagen

  • Bente Kiens, Professor · University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-23
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05426447 on ClinicalTrials.gov